Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension.
Saved in:
| Title: | Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension. |
|---|---|
| Authors: | Adeshara K; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Lithovius R; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Mutter S; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Harjutsalo V; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Lehto M; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Groop PH; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia. per-henrik.groop@helsinki.fi.; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. per-henrik.groop@helsinki.fi., Sandholm N; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland. niina.sandholm@helsinki.fi.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. niina.sandholm@helsinki.fi.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. niina.sandholm@helsinki.fi. |
| Corporate Authors: | FinnDiane Study Group |
| Source: | Cardiovascular diabetology [Cardiovasc Diabetol] 2025 Dec 12; Vol. 25 (1), pp. 13. Date of Electronic Publication: 2025 Dec 12. |
| Publication Type: | Journal Article; Observational Study |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
